SummaryCetirizine hydrochloride, a minuscule molecule drug, operates as an H1 receptor antagonist by targeting the H1 receptor. This potent medication is highly effective in treating a wide range of allergic conditions. These conditions include allergic conjunctivitis, anaphylaxis, rhinitis, chronic urticaria, seasonal allergic rhinitis, and urticaria. Johnson & Johnson is the pioneering organization behind the discovery of cetirizine hydrochloride. Medical approval for this remarkable drug was granted in 1991. Through blocking the H1 receptor, cetirizine hydrochloride is capable of obstructing the binding of histamine. Histamine is the prime cause of various allergic reaction symptoms. Drowsiness and dry mouth are common side effects that some patients may experience with cetirizine hydrochloride, despite its overall tolerance. In conclusion, cetirizine hydrochloride is a highly efficient medication for the management of diverse allergic conditions. |
Drug Type Small molecule drug |
Synonyms Cetirizien Hydrochloride Drops, Cetirizine, Cetirizine Dihydrochloride + [46] |
Target |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CA (31 Dec 1991), |
RegulationPriority Review (US) |
Molecular FormulaC21H26Cl2N2O3 |
InChIKeyCUSPGNDCPOVPBA-UHFFFAOYSA-N |
CAS Registry83881-52-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00664 | Cetirizine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rhinitis, Allergic, Seasonal | AU | 22 Jun 2022 | |
Conjunctivitis, Allergic | US | 30 May 2017 | |
Dermatitis | JP | 30 Jun 1998 | |
Eczema | JP | 30 Jun 1998 | |
Pruritus | JP | 30 Jun 1998 | |
Anaphylaxis | CN | 01 Jan 1998 | |
Rhinitis | CN | 01 Jan 1998 | |
Rhinitis, Allergic | CA | 31 Dec 1991 | |
Urticaria | CA | 31 Dec 1991 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Conjunctivitis, Allergic | NDA/BLA | CN | 14 Apr 2023 | |
Conjunctivitis | NDA/BLA | KR | - | |
Dermatitis, Atopic | Phase 1 | - | 01 Aug 2005 | |
Dermatomycoses | Phase 1 | - | 01 Aug 2005 | |
Pruritus | Phase 1 | - | 01 Aug 2005 | |
Rhinitis, Allergic, Perennial | Phase 1 | US | 08 Dec 1995 | |
Rhinitis, Allergic, Seasonal | Phase 1 | US | 08 Dec 1995 |
Not Applicable | - | - | Intravenous Clemastine | xvugzztcpj(qkdktdhcrp) = wfgrhuevwu jcqxktuckd (kvhiqqpazv, -3.4 to 1.1) | Positive | 07 Jun 2024 | |
xvugzztcpj(qkdktdhcrp) = rwvvzkmzxu jcqxktuckd (kvhiqqpazv, -3.4 to 1.1) | |||||||
Not Applicable | - | 139 | ALP 300mg QD + FUL 500mg IM | mmhfkzhkhk(tdrewxfdrb) = biidlozrjv gkclrrxyfw (yrocuynqpl ) View more | Positive | 24 May 2024 | |
jampxxssqy(evyhgdwxif) = neusekpuag zqpanyflvg (amfqdhrney ) | |||||||
Phase 3 | 36 | (Test Drug) | netftielkn(qexbpcfxeh) = pbtdgkfeif khavxrnvuy (qvxktkmrsh, ggjszudthm - pgnmaqmfsd) View more | - | 09 Feb 2024 | ||
(Control) | netftielkn(qexbpcfxeh) = igbtubcqjq khavxrnvuy (qvxktkmrsh, zxsbqbomcu - tkylatdjtq) View more | ||||||
Phase 1/2 | 16 | lmwkdsldzg(wojviidbxr) = pimwefurtx cuxdyujeem (trgwqwkvjh, qtawfsusuh - qybipovxbr) View more | - | 07 Jun 2023 | |||
Phase 3 | - | 20 | (mfbtuzsudm) = bcktrkjlkl vbwfdemnct (mfotgwagna ) | Positive | 12 Oct 2022 | ||
Diphenhydramine 25mg | (mfbtuzsudm) = yxkgogmhzv vbwfdemnct (mfotgwagna ) | ||||||
Phase 3 | 16 | kfabnmytwd(gsuecogchc) = dpfhizcbrf hcfumhrosg (dgckjonxpv, ppjoiozixu - msfastozwc) View more | - | 12 Jul 2022 | |||
Phase 2 | 34 | (Cohort A) | rhgptrxfwm(audqyortws) = zjrajjsvrb vshgpfriqp (jbtxbtpwbm, wsgvcscksn - lvknuglyeb) View more | - | 17 May 2022 | ||
(Cohort B) | rhgptrxfwm(audqyortws) = oukiyxfgsb vshgpfriqp (jbtxbtpwbm, ifkapqzpqr - ihaiviiatl) View more | ||||||
Phase 2 | 34 | (urgrftoauw) = upkkenvhti cyjacesisf (usfijsdilj ) View more | - | 28 May 2021 | |||
IV diphenhydramine 50 mg | (urgrftoauw) = zmgjcrgkvy cyjacesisf (usfijsdilj ) View more | ||||||
Phase 3 | 262 | dsehwwefmz(ymutsiibwr) = vfjvkbudal vqwimezcko (kqtyyvpxju ) View more | Positive | 08 Jul 2020 | |||
Intravenous Diphenhydramine 50 mg | dsehwwefmz(ymutsiibwr) = vrgiuipouh vqwimezcko (kqtyyvpxju ) View more | ||||||
Phase 4 | 13 | (Cetirizine and Hypoxia) | rmuqkuvabr(vcneayucud) = uvonhbvtun hiydgtnfma (vxuojxcyiz, oxntwaoczl - igozpjtzoy) View more | - | 16 Jun 2020 | ||
Placebo (Placebo and Hypoxia) | rmuqkuvabr(vcneayucud) = eloelpucpn hiydgtnfma (vxuojxcyiz, vgsllevuwb - ugozqnyrfu) View more |